Pulsenmore Secures First U.S. Commercial Agreement for Home Ultrasound with Leading Medical Center

summarizeSummary

Pulsenmore Ltd. announced its initial commercial engagement in the U.S. with the Center for Fetal Medicine & Women's Ultrasound, marking a significant step following recent FDA approval for its home pregnancy ultrasound product.

check_boxKey Events

• First U.S. Commercial Engagement

  Pulsenmore announced its initial commercial engagement in the United States, a significant milestone following its recent FDA approval.

• Partnership with Leading Medical Center

  The company entered a services agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles, California.

• Deployment of Home Ultrasound Services

  CFFM will purchase Pulsenmore ES home ultrasound services, enabling remote patient monitoring and reducing unnecessary clinic visits.

• Focus on High-Risk Pregnancies

  CFFM specializes in obstetric care for high-risk pregnancies, managing approximately 1,500 pregnancies per year, highlighting the clinical utility of Pulsenmore's technology.

auto_awesomeAnalysis

This 6-K filing details Pulsenmore's critical entry into the U.S. market, following its recent FDA clearance. The agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles represents the company's first commercial engagement in the United States, validating its home ultrasound technology for remote prenatal monitoring. This strategic partnership with a center specializing in high-risk pregnancies and managing approximately 1,500 pregnancies annually is a significant milestone for Pulsenmore's growth strategy and demonstrates the potential for its technology to improve access to obstetric healthcare services in the U.S.